Search This Blog

Tuesday, April 2, 2024

Ships escape Baltimore port after bridge collapse

Trapped vessels have started to escape Baltimore port following last week’s collapse of the Francis Scott Key Bridge.

A channel has been opened on the northbound side of the fallen crossing.

That’s allowing limited marine traffic to pass through.

The first vessel was a tug pushing a barge full of jet fuel for the Department of Defense.

However, much of the channel remains blocked by wreckage and the giant container ship Dali, which struck the bridge and brought it down.

That means it could be a long time before commercial shipping can get back to normal at the port - a key gateway for exports of farm goods and other products.

Maryland Governor Wes Moore says no effort will be spared to restore the crossing and restart cargo movements:

“We cannot rebuild the bridge until we clear the wreckage. But I'm telling you, we are going to get this done. We will clear the channel. We will move the Dali. We will rebuild the Francis Scott Key Bridge.”

Efforts are under way to remove the wreckage, but it’s no easy task.

Officials say it’s so tangled that it’s hard to know where to cut.

Recovery workers needed 10 hours to free and remove one 200-ton piece of debris.

And they described that as a “relatively small lift”.

The Coast Guard says the situation is even worse underwater, where visibility is limited by the sheer volume of debris.

That all leaves officials unwilling to estimate how long the clear-up could take.

On Friday, U.S. President Joe Biden will get a first-hand look at the problem when he visits the area.

The administration is working with Congress to ensure that the federal government pays to rebuild the bridge.

https://finance.yahoo.com/video/ships-escape-baltimore-port-bridge-052328064.html

Vaccinated Show Long COVID-Like Symptoms With Detectable Spike Proteins: Preprint Study

  by Marina Zhang via The Epoch Times (emphasis ours),

Spike protein could remain in immune cells for more than 245 days following vaccination, according to a recent preprint. The study evaluated 50 patients who developed long COVID-like symptoms after the COVID-19 vaccine; none had been infected with the virus.

The authors extracted immune cells from 14 post-vaccine patients and found that 13 had spike protein in their immune cells. Asymptomatic vaccinated people had no spike present.

Researchers from InCellDx, a research company that produces panels and protocols that test for and treat long COVID and post-vaccine syndrome, authored the paper.

Their previous study published in 2022 showed that unvaccinated long-COVID patients could have spike protein persist in their immune cells for 15 months.

In both papers, the spike proteins were detected in monocytes, immune cells that circulate the body.

These findings indicate that the persistence of these spike proteins was likely the driver for the symptoms of long COVID and post-vaccine syndrome, InCellDx founder and lead study author Dr. Bruce Patterson told The Epoch Times.

These cells bind to the blood vessels. They cause endotheliitis (inflammation of endothelium) and vascular inflammation, which I think now has been corroborated by many as being probably one of the most important pathogenic mechanisms in long COVID,” Dr. Patterson said.

Spike Protein Reservoirs

Monocytes are scavenger cells of the immune system,” Dr. Patterson said. Monocytes function similarly to how the video game character Pac-Man does: They roam the body and gobble up proteins they come across in their way.

In long COVID, monocytes gobble up spike protein, the virus’ viral debris. In post-vaccine syndrome, the monocytes engulf spike proteins, which the body makes from the COVID-19 vaccine.

These spike proteins are then stored inside the monocytes, which causes the cells to live longer than they should. The prolonged longevity can cause inflammation, leading to various long-lasting symptoms.

In the study, Dr. Patterson and his team observed that post-vaccine patients had significantly higher monocyte levels than those without post-vaccine symptoms. The symptomatic post-vaccine patients also had a clear elevation in inflammatory biomarkers, whereas the asymptomatic patients did not.

Dr. Patterson believes that at the time of the study, viral replication or spike protein production from vaccinations was no longer occurring. Instead, the spike proteins persisted for months because they were being stored.

He reasoned that once the monocytes engulfed the spike proteins, the spike hijacked the cells’ cell death program, turning off cell death “so they become long-lived cells.”

A similar phenomenon occurs with the HIV and hepatitis C viruses.

Monocyte cells can cause inflammation. Particularly, nonclassical monocytes, which traverse the blood vessels, can lead to blood vasculature inflammation and damage.

Several studies have identified inflamed and damaged vasculature as central features of long-COVID symptoms. These patients have a high level of inflammatory chemicals, which can promote fatigue, blood clotting, immune and nervous system dysregulation, and more.

Long COVID vs. ‘Long Vax’

The recent preprint also shows how long COVID and post-vaccine syndrome may be differentiated.

While the same thing—spike protein persistence—likely causes both conditions, the conditions have slightly differing chemical profiles, especially regarding the level of interleukin-8, or IL-8.

IL-8 is a type of cytokine that aids in attracting immune cells to areas of inflammation, Dr. Patterson explained.

He said that medication that blocks these different cytokines should resolve symptoms. For example, his team found that tumor necrosis factor-alpha (TNF-alpha) is a cytokine that, when elevated, induces fatigue. Therefore, reducing that cytokine can help diminish fatigue.

Other cytokines shared between long COVID and the condition dubbed “long vax” include sCD40L and CCR5, which drive vascular inflammation. Another cytokine, IL-6, signals systemic inflammation.

Dr. Patterson explained that the two conditions’ distinct chemical profiles may be due to their different delivery mechanisms: Viral infection causes long COVID, while inoculation causes post-vaccine syndrome.

Treatment Protocol

Dr. Patterson uses the same protocol for treating long COVID and post-vaccine syndrome. Both treatments entail curbing inflammation in the blood vessels and throughout the body.

His protocol includes using maraviroc, an HIV drug, and atorvastatin, a type of statin, to target vasculature inflammation.

Maraviroc blocks CCR5, a type of inflammatory cytokine that causes blood vessel inflammation, while statins can bind to the receptors inside the blood vessels, blocking them from binding to inflammatory monocytes.

Many doctors have found successes with ivermectin, N-acetylcysteine (NAC), and nattokinase, all of which are drugs and nutraceuticals that help break down outside spike protein. However, Dr. Patterson reported the opposite in his practice. He explained that the drugs cannot target the spike protein stored inside cells.

In February, the U.S. Food and Drug Administration (FDA) approved Dr. Patterson’s clinical trial to test a maraviroc and statin combination for treating long COVID.

Long Vax Masked as Long COVID

The study findings imply that some people diagnosed with long COVID may actually be suffering from post-vaccination symptoms.

Evidence they blame vaccine injury on ’long covid’?,” Dr. Lynn Flynn, a virology and infectious disease expert, wrote on X, citing the preprint.

Dr. Patterson said that the symptoms being reported in these post-vaccine patients “were almost identical to the symptoms in long COVID,” with the predominant symptoms being fatigue, neuropathy, brain fog, and headache. Long-COVID patients in another cohort also reported these symptoms.

[Long vax] has a very low prevalence, but because billions of [people] are vaccinated, there’s a great number of individuals who have long vax,” he added.

Apart from post-vaccine syndrome, Dr. Patterson said that patients with an exacerbation of Lyme disease and myalgic encephalomyelitis (chronic fatigue syndrome) have also been labeled as long-COVID patients due to a symptoms-based diagnosis.

https://www.zerohedge.com/medical/vaccinated-people-show-long-covid-symptoms-detectable-spike-proteins-preprint-study

Monday, April 1, 2024

Took Ozempic, didn't lose weight

 Here’s a sad jab of the truth.

More evidence is coming out that pricey semaglutides like Ozempic and Wegovy — diabetes medications lauded for secondary weight loss capabilities through appetite suppression — aren’t necessarily helping as many people shed pounds as previously thought.

“There was appetite suppression the first 1½ months but it’s kind of just fallen off after that,” Nashville, Tennessee, resident  Melissa Traeger, 40, told the Wall Street Journal regarding her lack of success on the medication type, also known as GLP-1s.

At first, the 300-pound Traeger quickly dropped 10 pounds, but the next five came more stagnantly — and then she said no more weight was lost.

Another man, Anthony Esposito, 68, of Austin, Texas, saw no success on either Ozempic or Wegovy, just feelings of sickness while he took them.

“It did not budge the needle,” he said.

Traeger and Esposito are among many frustrated users, according to the Journal, which also cited a trial that showed only about 14% of patients cut more than 5% of bodyweight, while only one-third lost 10% of it.

Another report published on Epic Research saw that 17.7% of semaglutide users regained all of their weight — if not more — upon stopping.

Ozempic apparently isn’t helping as many people as typically thought.Wild Awake – stock.adobe.com

Doctors have also observed many “non-responders” — about 10% to 15% of people who lose 5% or less of their body weight.

“There’s going to be extreme variability in how people respond,” Dr. Eduardo Grunvald, an obesity-medicine physician at UC San Diego Health, told the Journal.

Grunvald added that issues of weight gain may go beyond something in hormones that the drugs imitate to regulate appetite. He also said that peoples’ other medical issues may play a factor, such as how those with Type 2 diabetes typically lose less than those without the disease.

The doctor added that prior exercise and eating habits before starting the drugs are also highly influential factors.

Those who have made healthy lifestyle changes and already lost weight likely don’t get that much added bonus from the medications.

People who have struggled with obesity for a lifetime may additionally have a genetic mutation that prevents the drugs’ potency, according to Dr. Steven Heymsfield of Louisiana State University’s Pennington Biomedical Research Center.

Some patients on drugs like Ozempic aren’t losing weight.myskin – stock.adobe.com
Drugs like Ozempic reportedly aren’t showing be-all, end-all impacts on patients’ lives.Natalia – stock.adobe.com

He added that those who can metabolize drugs quickly also might not see much out of them in this case.

Taking other medications as well, especially antipsychotics or antidepressants, can be associated with weight gain as a side effect.

“You could have some other drug interactions that prevent the effect of the GLP-1 drugs from working,” Heymsfield told the Journal.

https://nypost.com/2024/04/01/lifestyle/we-took-ozempic-thinking-wed-lose-weight-we-didnt-and-heres-why/